Home / Community / News / News


01/14/2016 - 12:32pm

Word came from the FDA on January 14th that it would not approve the new drug application for "Kendrisa,"  Biomarin's antisense-oligo based drug for Duchenne muscular dystrophy.

01/14/2016 - 11:59am

End of year donations were more generous than ever this year, inspired in part by a $15,000 match contributed by the Boekelmann family, bringing us to over $1.1M in total 2015 contributions. A huge thank you to each and every one of you for being part of this special community and helping to sustain it. Happy New Year!

01/14/2016 - 8:35am

MDF just kicked off the new year with our annual two-day strategic planning offsite. The planning team included DM researchers, board members and staff. Read on for some highlights of our plans for 2016 and progress to date on our 3-year drug development acceleration effort, MDF 3.0: Driving Drug Development.

12/30/2015 - 9:17am

Many MDF community members are aware of an important, multi-year MDF effort -- MDF 3.0: Accelerating Drug Development -- because we published an article on the launch of this initiative in early 2015. Read a full report on the first-year results of MDF 3.0: Accelerating Drug Development, and the initiatives we are pursuing to promote the development of new DM therapies.  

12/10/2015 - 4:18am

Established by the MD CARE Act in 2001, the Muscular Dystrophy Coordinating Committee (MDCC) is a federal advisory committee composed of representatives from major government agencies relevant to muscular dystrophy and a selection of “public” members representing patients and disease advocacy associations. The Commi



© Myotonic Dystrophy Foundation. All rights reserved.